Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02026908 · ClinicalTrials.gov registry record · NA

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

A NA study, sponsored by Northwestern University.

Completed
Registry status
NA
Development phase
45
Enrollment target

NCT02026908 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 45 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02026908, a NA study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target

Study Summary

This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).

Interventions

  • DEVICE Prostate Artery Embolization

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2014-01-01
Est. Completion 2023-03-27
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT02026908

The ClinicalTrials.gov registry entry for NCT02026908 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Prostate Artery Embolization is the first listed.

NCT02026908 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02026908 about?

NCT02026908 is a clinical study titled "Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)". This is an open-labeled, non-randomized feasibility study to evaluate the safety of prostate artery embolization (PAE) for the treatment of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH).

What is the current status of trial NCT02026908?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2014-01-01. Estimated completion is 2023-03-27.

What interventions are being tested in trial NCT02026908?

The interventions under investigation include: Prostate Artery Embolization (DEVICE).

Who is sponsoring clinical trial NCT02026908?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.